Canadian Medical Marijuana & Cannabis Industry News Europe Cannabis Industry & Marijuana Business News Featured Marijuana Business & Cannabis Industry News GW Pharmaceuticals International Marijuana Business News Jazz Pharmaceuticals United States Cannabis Industry & Marijuana Business News

Medical cannabinoid firm GW Pharma to be acquired by Jazz Pharmaceuticals for $7.2 billion

Global pharma company Jazz Pharmaceuticals has reached an agreement to buy U.K.-based GW Pharmaceuticals, one of the largest medical cannabinoid businesses in the world, for $7.2 billion in cash and stock, the drugmakers announced Wednesday.
Medical ca…

Cannabis Industry & Marijuana Business Briefs Europe Cannabis Industry & Marijuana Business News GW Pharma GW Pharmaceuticals International Marijuana Business News United Kingdom

GW Pharma expects fiscal 2020 sales to reach $526 million

United Kingdom-based GW Pharmaceuticals expects to report annual sales of approximately $526 million for the year ended Dec. 31, 2020, it said in a preview of its fourth quarter and full-year results. Fourth quarter net sales will be approximately $148…

Danish denmark Epidiolex Europe Cannabis Industry & Marijuana Business News Featured Marijuana Business & Cannabis Industry News GW Pharmaceuticals International Marijuana Business News Marijuana Industry Statistics, Data and Charts

Denmark medical cannabis sales post a positive quarter thanks to Epidiolex

Sales of medical marijuana in Denmark posted healthy gains in the third quarter of 2020, coinciding with the launch of GW Pharmaceuticals’ cannabis drug Epidiolex. Overall sales of all medial cannabis products grew from about 13 million Danish Kr…

Cannabis Industry & Marijuana Business Briefs Europe Cannabis Industry & Marijuana Business News GW Pharma GW Pharmaceuticals International Marijuana Business News United Kingdom

Epidiolex maker GW reports record quarterly revenue of $137 million

United Kingdom-based GW Pharmaceuticals posted higher revenue in the quarter ended Sept. 30, largely driven by sales of its cannabidiol medicine Epidiolex in the United States. GW’s total revenue for the third quarter reached $137.1 million, abou…

Asia & Oceania Cannabis Industry & Marijuana Business News Australia Cannabis Industry & Marijuana Business Briefs Epidiolex Epidyolex GW Pharmaceuticals International Marijuana Business News Medical Cannabis Industry & Recreational Marijuana Business News

GW Pharmaceuticals cannabis drug gets regulatory OK in Australia

GW Pharmaceuticals’ plant-derived CBD drug Epidyolex received approval from Australia’s Therapeutic Goods Administration (TGA) to be used in treating seizures related to Lennox-Gastaut syndrome and Dravet syndrome for patients 2 and older. …